

IN THE CLAIMS:

1-20 (Canceled).

21. (amended) ~~The~~ A method of ~~claim 20~~ detecting and identifying
markers indicative of early stage cancer by:

differentially biopanning sera obtained from a normal individual and
patients with early stage cancer against epitope-expressing phage display
libraries;

obtaining epitope bearing clones displaying reactivity to antibodies present
in sera of patients with early stage cancer but not in sera of normal individuals,
including the step of identifying and excluding the sera of normal individuals
that react strongly but nonspecifically to epitope bearing clones, wherein
further including the step of excluding the sera of normal individuals which
react strongly but nonspecifically to epitope bearing clones further includes the
step of excluding sera which show a unimodal pattern of dual fluorescence
reaction with epitope bearing clones, where a first color indicates reaction with
human immunoglobulin and a second color indicates reaction to phage capsid
proteins-;

identifying all epitopes that are specific to early stage cancer as markers
indicative of early stage cancer; and

including all epitopes identified as markers in a microarray assay designed
to detect early stage cancer.

22. (Cancelled).